Ultimo aggiornamento :
28/04/2024
Le squadre di ricerca - Clinical Pharmacy Department, University Hospital Necker-Enfants Malades   Pdf  
Francia
Ospedale
Clinical Pharmacy Department, University Hospital Necker-Enfants Malades
Paris
Bibliografia   Bibliografia   (11)  
1
Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease.
Querin B, Schweitzer-Chaput A, Cisternino S, Auvity S, Fauqueur A-S, Negbane A, Hadchouel A, Schlatter J, Cotteret C. (salvatore.cisternino@aphp.fr)
Pharmaceutics - 2023 - ,15, 957.
2
Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D, Secrétan P-H, Cotteret , Jacques-Gustave E, Greco C, Bodemer C, Schlatter J, Cisternino S. (philippe-henri.secretan@u-psud.fr)
Molecules - 2022 - ; 27(3): 1070.
3
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease.
Hinterlang M, Sebti M, Cotteret C, Vidal F, Neven B, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
The Scientific World Journal - 2022 -
4
Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
El Mershati S, Thouvenin A , Secretan P-H, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
Pharm Dev Technol - 2021 -
5
Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags.
Vidal F, Cotteret C, Negbane A, Sebti M, Hinterlang M, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
EJHP - 2021 -
6
Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions.
Ancedy D, Sebti M, Postaire M, Vidal F, Cisternino S. ()
Am J Hosp Pharm - 2021 - ;78,9:825–831
7
Voriconazole topical cream formulation: evidence for stability and antifungal activity.
Bouchand C, Nguyen D, Secretan P-H, Vidal F, Guery R, Auvity S, Cohen J.F, Lanternier (joel.schlatter@aphp.fr)
Int J Antimicrob Agents - 2020 - ; 56: 106083.
8
Stability of warfarin sodium flavoured preservative-free oral liquid formulations.
Schlatter J, Cisternino S. (joel.schlatter@ aphp.fr)
EJHP - 2018 - ; 25, e2
9
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions.
Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Do Nascimento Afonso V. ()
Int J Pharm Compound - 2015 - ; 19, 1: 73-77.
10
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition.
Bourget P, Amin A, Vidal F, Pieyre M, Dosso E.O, Beauvais R, Loeuillet R. ()
Int J Pharm Compound - 2014 - ; 18, 5: 427-431.
11
How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?
Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus J.C, Jouani B.-L., Merlette C, Nov?-Josserand R, Pages J, Panzo R (philippe.bourget@nck.aphp.fr)
Antimicrob Agents Chemother - 2014 - ; 58 : 2849-2855.

Elenco delle molecole   Molecole studiate   (11)  
Immunosoppressore Soluzione orale Azathioprine
Antibiotico Iniezione Ceftazidime
Farmaco contro il cancro Unguenti Erlotinib
Antinfiammatorio Soluzione orale Hydrocortisone
Antinfiammatorio Soluzione orale Hydroxychloroquine sulfate
Anestetico generale Soluzione orale Ketamine hydrochloride
Altro Soluzione orale L-Methionine
Farmaco contro il cancro Iniezione Pemetrexed diarginine
Farmaco contro il cancro Soluzione orale Ruxolitinib
Antimicotico Unguenti Voriconazole
Anticoagulante Soluzione orale Warfarin sodium

  Mentions Légales